A “state-of the art” update on prostate cancer management

The March issue of The ASCO Post, just out this morning, includes a brief article based on conversations by Dr. Richard Boxer with Dr. Peter Scardino (of Memorial Sloan-Kettering Cancer Center in New York) and Dr. Howard Sandler (of Cedars-Sinai Medical Center in Los Angeles) held at the Gentourinary Cancers Symposium.

The article provides a summary of Dr. Scardino’s and Dr. Sandler’s current views on a whole range of issues from screening, pre-treatment imaging studies, and focal therapy to the future evolution of radiotherapy in the management of prostate cancer. Given the stature of these two opinion-leaders in the prostate cancer research and treatment communities, their opinions are always worth paying attention to. However, the article is generally limited to the diagnosis and management of men with localized forms of prostate cancer (as opposed to advanced and metastatic disease).

The same issue of The ASCO Post also includes an article on ipilimumab in the treatment of advanced forms of prostate cancer (based on presentations at the Genitourinary Cancers Symposium by Dr. Charles Drake and others). The value of ipilimumab in the treatment of advanced and progressive forms of prostate cancer is yet to be firmly established.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: